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Abstract
Medication Assisted Treatment:
Examining Enrollment and Demographic Factors of Treatment
by
Antwana Letoya Drayton, M.S.
Committee Chair: Patrick J. Aragon, Psy.D.

Opioid Use Disorder (OUD) has been a long-standing epidemic concern related to
the continuous growth of variations of the substance and its’ potency. Due to the
versatility of the substance to be both an illicit drug and also a prescription
medication, the interest in controlling and monitoring its’ use creates a greater
public health concern. Treatment overtime has been revitalized to directly address
the social, biological, and physiological difficulties of patients with OUDs.
Medication Assisted Treatment (MAT) has been explored and has become one of
the most widely used plans for treatment of Substance Use Disorders (SUDs)
related to pain management issues, dependency, withdrawal, and likelihood of
maintaining sobriety. The use of MAT has been proven to be a positive and
worthwhile addition to the treatment of OUDs. However, there are gaps in the
administration and enrollment of individuals into the programs and facilities that
offer MAT services. As this deficit is acknowledged, the current study was posed to
examine the relationships among demographic factors relative to OUDs and MAT
services. Data from a sample of 973 adults with a diagnosis of OUD relative to all
opioid related substances, was analyzed in this study. Relationships among gender,
race, employment, education, and types of treatment were explored. Types of
treatment included Suboxone and Vivitrol. Overall, this study found that Suboxone
treatment was administered more often than Vivitrol treatment. Also, outpatient
service members used MAT services more often than inpatient members. Chisquare analyses and an Analysis of Variance were both utilized, indicating gender
differences and educational differences. Likewise, specific race differences and
employment attainment computed no significant conclusions. Contributions to the
findings, limitations of the exploration, and future research directions are all
discussed.
Keywords: demographics, treatment, recidivism, medication, opioid, Vivitrol,
Suboxone
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Chapter 1
Medication Assisted Treatment: Examining Enrollment and
Demographic Factors of Treatment
Individuals have been utilizing mind-altering and mood-altering substances
throughout history so understanding the nature of illicit drug abuse and addiction is
pivotal to addressing the substance use (Musto, 1996). However, scientific and
technological advances have led to an increase in substance potency and the
creation of new substances. These shifts create noted substance use difficulties that
emerge with each variation of these naturally-occurring substance forms. The
depiction of these substances often used for healing has undergone significant
scrutiny when the chemical makeup creates more addictive difficulties than positive
outcomes. These addictions increase the importance of addressing and monitoring
the costly and often tragic effects and impacts of use. Specifically, the use of
opioids and the continuous altering of the substance warrants exploration due to the
constant shift of production and therefore treatment of those with related ailments.
As such, this project seeks to review how opioid addiction, is treated in
facilities that are capable of providing specific medication services. The focus is on
the way in which these services affect various demographically different
populations in an attempt to gain greater understanding of gaps in treatment and
necessary educational areas. This study is to investigate enrollment to the
medication services to further explore factors that are likely to benefit or hinder
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treatment. Therefore, review of opioid use components, historical and current
treatment options, and future directions are all to be explored in this research.
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Chapter 2
Review of the Literature
The theme of substance use continues to negatively impact individuals' lives
and their family, school, workplace, and community roles. It is reported that over 2
percent of the worlds' population has alcohol or illicit drug addiction (Ritchie,
2019). What has become evident is that the amount of destruction experienced by
the individuals and those closest to them exceeds intoxication, addiction, and
dependence. More specifically, drug use is reported to be responsible, both directly
and indirectly, for more than 11.8 million deaths per year. Directly, drug use results
in over 350,000 overdose deaths yearly. Indirectly, the use of these substances
affects mental and physical health, causing premature death related to the disease
by way of various risk factors (GBD, 2017). Risk factors such as environmental
markers are essential to consider when evaluating the likelihood of sustained
recovery and medication access. However, the financial costs of treatment and lack
of adequate resources contribute to disparities in substance abuse treatment
completion, identifiable within socioeconomic factors differences (Guerrero et al.,
2013; Saloner & Cook, 2013). Therefore, this study will examine the utilization of
treatment options relative to identified demographic and ecological factors
associated with Opioid Use Disorder (OUD).
Diagnostic Considerations of Substance Use Disorders
The historical conceptualization of substance use and the diagnostic criteria
have all undergone much change over time. The terms, dependence, and abuse,
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previously represented different disorder criteria which allowed for a distinction
that explained a strength hierarchy (Hasin et al., 2013). These terms also denoted a
degree of severity relative to the level of treatment and primary symptomatology
(Rhemtulla et al., 2016). However, research has suggested that merging the
identifiers of abuse and dependence into a single substance use disorder could
resolve the discrepancies presented in the previous separation of the symptoms into
separate identifiers. Likewise, the two tend to be identical instead of mutually
exclusive presentations of separate disorders (Kopak, Proctor, & Hoffmann, 2014).
Therefore, a substance use disorder is represented as the recurrent use of
alcohol and substances causing clinically and functionally significant impairment,
relative to the set of criteria established for eight different categories of substancerelated disorders and diagnostic severity levels (American Psychiatric Association,
2013; Horvath, Misra, Epner, & Cooper, 2016). The disorder's characteristics are
specific to markers used to illustrate the components of the substance and
pharmacological representations. Additionally, a substance use disorder is denoted
as a behavior pattern exemplified by continued use of a substance, although it noted
detrimental and consequential results (Straub, 2014).
For this study, OUD will be extensively reviewed. The death rate from
accidental drug overdose for individuals under 50 has exceeded firearms, car
accidents, homicides, or HIV/AIDs (CDC, 2018). Despite the existing challenges
faced amongst many other substances, each day, more than 115 people in the
United States die due to an opioid overdose (Verdugo, Farber, Selters, Stout, &

MEDICATION ASSISTED TREATMENT

5

Wagner, 2019). This information is essential because the utilization of opioids is
now more related to treating acute and chronic pain. Consequently, the
development of an OUD depends on factors that include the length of time a person
is prescribed opioids for acute pain and the length of time the person continues
taking opioids (CDC, 2018). Likewise, OUD treatment also faces many challenges,
such as regulation for treating chronic pain, efficient detoxification protocols, and
successful relapse prevention techniques. Therefore, medication-assisted treatment
(MAT) navigates this complex system and makes the distribution and management
of this substance the primary focus of study.
Opioid Use Disorder
Of the eight categories listed in the DSM-V for diagnostic considerations,
OUD is included and specific to this study. Opioids are a class of drugs that
includes prescription pain relievers, oxycodone, hydrocodone, codeine, morphine,
fentanyl, and heroin (Maglione et al., 2018; National Institute of Drug Abuse,
2015). There are continued fluctuations of opioid users from one substance to
another, both across a population and within individual case histories. The impact
continues to be acknowledged in cases of users in medical and non-medical fields.
Historically, Opioids were utilized as a common pain medication within medical
operations, traumatic injuries, and even common coughs and sleeplessness (CDC,
2018; Świeboda, Filip, Prystupa, & Drozd, 2013). However, the awareness of
differences in potency and chemical compositions created a need for a controlled
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administration of the substance, which exposed potential misuse, leading to
addiction and, ultimately, the disorder.
Biological Component of Opioids. Opioid receptors are widely studied.
Due to their crucial role in mood disorders, pain management, and drug addiction,
research is utilized to establish structural and mechanistic insights into their
purpose and function (Shang & Filizola, 2015). Opioid receptors belong to the Gprotein coupled receptors. These receptors are the most abundant class of cellsurfaced receptors and the target of at least one-third of approved and marketed
drugs (Vortherms and Roths, 2005). The four major subtypes of opioid receptors
are the Delta, Mu, Kappa, and Zeta receptors. They mediate the human body's
response to most hormones, neurotransmitters, drugs. They are also involved in the
sensory perception of vision, taste, and olfaction (Dhaliwal and Gupta, 2019). The
traditional model proposes that the binding of an opioid to a receptor activates an
associated G-protein, which then triggers a biological response (Filizola and Devi,
2012). Different types of opioid receptors bind to their respective agonist
counterparts. Dopamine is responsible for the rewarding effects produced by opioid
administration that lead to positive reinforcement. However, similar to positive
reinforcement are the issues and concerns that arise in terms of genetic variances
associated with increased dependence on opioids. Likewise, despite their analgesic
effects, opioid drugs are accompanied by various side effects. These side effects
include but are not limited to vomiting, nausea, constipation, tolerance, and
addiction (Feng et al., 2012).
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Use of Opioids for Pain Management. According to the Substance Abuse
and Mental Health Services Administration (SAMHSA), in 2016, 11.4 million
people (4.4 percent of the total population) misused opioids (McCance-Katz, 2018).
97.4 percent of people misused prescription pain relievers, and 8 percent of
individuals’ being heroin users. Moreover, 5.4 percent is a combination of
prescription and heroin users. Additionally, 2.1 million Americans were diagnosed
with OUD, and only 20 percent of individuals with OUDs received specialty
addiction treatment.
In 2018, Florida providers wrote 53.7 opioid prescriptions for every 100
people, compared to the average U.S. rate of 51.4 opioid prescriptions (NIDA,
2020). Of the 4,698 reported drug overdose deaths in Florida in 2018, nearly 68
percent (3,189 fatalities) involved opioids. Deaths involving synthetic opioids other
than methadone (mainly fentanyl and fentanyl analogs) were high at 2,091but
remained stable. Similarly, deaths involving heroin and prescription opioids
remained steady at 680 and 1,282 in 2018. Related to Neonatal Abstinence
Syndrome (NAS) and Neonatal Withdrawal Syndrome (NOS), which occurs when
a woman uses opioids during pregnancy, the 2017 rate of NAS/NOWS in Florida
was 7.3 cases per 1,000 hospital births (NIDA, 2020).
The Opioid Epidemic
The consensus on addiction is represented as an ongoing yet fixable brain
disease categorized by compulsive substance abuse and repeated relapse (APA,
2017). As it relates to this study, it is vital to understand the historical
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demographics of users. The opioid epidemic marks a timeframe where opioid
overdose deaths and complications overshadowed that of all other drugs combined.
Over time, the trends are illustrated in shifts of the opioids utilized, population, and
surrounding factors. In the 1960s, the population of heroin users was predominantly
men (82.8 percent, with a mean age of 16.5 years), with their first experience of
opioid use being heroin (Cicero, Ellis, Surratt, & Kurtz, 2014; NIDA, 2020). Both
White and non-White individuals were using before the 1980s. However, more
recent individuals using opioids were introduced by prescription drugs in less urban
areas and predominantly White. Specific to this study, Florida trends,
demographics, and complications are explored closely.
The data from the Florida Department of Health's Bureau of Vital Statistics
informs that Florida's drug overdose deaths more than doubled from 2014 to 2016,
with 2,175 deaths in 2014, 2,805 in 2015, and 4,672 in 2016 (Scott & Philip, 2016).
Florida's opioid overdose rate has reportedly tripled since the turn of the century,
according to the Drug Policy Advisory Council 2016 Annual Report. Florida has
since passed two essential laws to assist in combating the opioid epidemic: the
Prescription Drug Monitoring Program and House Bill 249 (Florida Department of
Health, 2020). The Prescription Drug Monitoring Program, also known as EFORSCE (Electronic-Florida Online Reporting of Controlled Substance Evaluation
Program), was created to encourage safer prescribing and reduce drug abuse. The
E_FORSCE requires controlled substance dispensers to report a controlled
substance in drug classifications, schedules II, III, IV, and V distributed to a patient
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and consulted the patient's distribution history system. Likewise, House Bill 249
requires reporting of controlled substance overdoses. These laws were directly
established to address the over-prescription of opiates and the resulting deaths.
Although Florida is the focus of this study, due to the facility explored, it is
important to understand and observe the waves and trajectory of the opioid
epidemic as a whole.
Waves of Opioid Use
The Center for Disease Control and Prevention (CDC, 2018) can outline the
rise in opioid-related overdose deaths in three distinct waves. The first wave
involved prescription opioids (natural and semi-synthetic opioids and methadone)
that increased since 1999. The second wave was activated in 2010, with a rapid
increase in overdose deaths related to heroin (CDC, 2018). Moreover, the third
wave began in 2013, with a significant increase in overdose deaths related to
synthetic opioids, explicitly connecting to illicitly manufactured fentanyl. The
market related to illicitly manufactured fentanyl continues to change and is often
used in combination with heroin, counterfeit pills, and cocaine (Drug Enforcement
Administration, 2019).
Relative to the established waves, the drug overdose death rate increased
significantly from 12.3 per 100,000 people in 2010 to 16.3 in 2015 (Rudd, Seth,
David, & Scholl, 2016). Also, from 2014 to 2015, the death rate from synthetic
opioids (including fentanyl) other than methadone increased by 72.2 percent, and
heroin death rates increased by 20.6 percent. All demographic groups, regions, and
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numerous states experienced an increase. The 63,632 drug overdose deaths in the
U.S. in 2016 represented a 21.4 percent increase from 2015, with two-thirds of
these deaths involving an opioid (Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019).
Additionally, from 2015 to 2016, drug overdose deaths increased in all drug
categories, with similar death increases involving synthetic opioids other than
methadone. Likewise, of the 70,237 drug overdose deaths in the U.S. in 2017,
47,600 involved an opioid (Wilson, 2020). While the number of overdose deaths
decreased by 4 percent from 2017 to 2018, the number of overdose deaths was still
four times higher in 2018 than in 1999, with nearly 70 percent of the 2018 deaths
involving opioids.
The First Wave. As of the 1990s, opioid use was explained in three waves
that varied for different populations. The first wave occurred among non-Hispanic
whites in medium-small metropolitan and non-metropolitan areas (Lippold & Ali,
2020). This utilization was in response to the overprescribing of opioid painrelievers, which resulted in increases in the rates of drug misuse and overdose
deaths. Additionally, prescriber bias contributed to the accessibility of opioid
prescription and subsequent misuse and overdose to white individuals instead of
their nonwhite counterparts (Lippold & Ali, 2020; Manchikanti et al., 2018).
The Second Wave. A second wave took place in the mid-2000s, with
widespread increases in prescription and non-prescription opioid overdose deaths.
With attempts to govern the number of prescriptions allotted, an increase in
potency and accessibility to heroin also took place. Therefore, in this wave, a
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transition from prescription opioid misuse to heroin took place (Lippold & Ali,
2020). Likewise, overdose deaths began to affect all populations, with opioid
prescription drug overdoses increasing in individuals with higher poverty levels. In
this wave, heroin use increased tremendously due to the shifts in opioid
prescription mandates and restrictions. The gap between users' populations began to
close as individuals could access heroin more straightforward and with less
regulation.
The Third Wave. However, due to illicit opioid use growth, the third wave
emerged around 2013. In this third wave, we received the introduction of overdose
deaths being contributable to synthetic opioids other than methadone. For instance,
illicitly composed fentanyl and similar synthetic opioids other than methadone
increased from 2010 to 2018 and surpassed heroin as the largest contributor to
opioid-related deaths in 2016 (Jones et al., 2018; Lippold & Ali, 2020 Scholl et al.,
2018; Wilson et al., 2020). This increase affected all populations. However,
minority groups witnessed a greater overdose death rate. Likewise,
misclassification of American Indian (A.I.) and Alaska Native (AN) race in death
certificates underestimated Washington's AI/AN overdose mortality by
approximately 40 percent (3). As a response to increases in regulations on
prescribers, such as the closing of pill mills and various Acts being put into place to
address the prescription accessibility, we witness a shift in potency, chemical
composition, and distribution, with heroin and synthetic opioids other than
methadone plaguing all surveyed populations.
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Treatment
Historically, addiction and mental illness were misunderstood and treated
with identical methods. Lack of understanding and technological advances
permitted the separation and hospitalization of individuals that did not fit into the
social norms. Before the 1800s, pain was regarded as a consequence of aging, and
therefore, no regulation of the use of substances such as cocaine and opioids
existed (Jones et al., 2018). This lack of regulation resulted in widespread
marketing and a prescription for many ailments (Meldrum, 2003). Around the
1900s- 1930s, continued discord was illustrated in treatment forms. Medical
supervisors of asylums and prisons were granted the authority to "asexualize" those
with mental health and substance use disorders, considering these individuals
degenerates (Stern, 2005). Also, street heroin abuse and iatrogenic morphine
dependence sparked the passing of the Harrison Control Act of 1914, which
influenced avoidance of opiates (Meldrum, 2003). This Act caused individuals to
be recognized as deluded and malingering and encouraged individuals in need of
opiates, such as cancer patients, to essentially avoid the medication until they likely
died (Jones et al., 2018). Another consequence of this Act was its restrictions of
prescribing to addicts eliminated a safe, legal way to obtain the substance. Attempts
at facilitating clinics and centers for morphine and narcotics were created but
closed for legal reasons, likely related to instances of inhumane and unlawful
research practices. (Kentucky Educational Television, 2017).
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Over time, the idea of treating pain and related under-treatment of pain was
revisited. Research and trials were again developed to address severe pain and the
positive or negative effects of opioid use. The World Health Organization (WHO)
and American Pain Society launched investigations into operational definitions of
pain and cancer treatment instead of chronic pain management (Campbell, 1996;
WHO, 1986). The Joint Commission published standards for pain management in
the 2000s that would require organizations to quantify pain assessments as
regulated by the Institute of Medicine (Baker, 2017). This publication facilitated
the need to prescribe opiates more generously with backing from pharmaceutical
companies, insurance companies, and federal healthcare funds allocated to those in
compliance.
However, the negative consequences became apparent in the physicians' felt
requirement to prescribe opiates. These consequences were illustrated in the overprescription of opiates, patient's reliance on the substance, pharmaceutical
companies introducing new formulations, and an overall increase of opioid
consumption (Tucker & Kathryn, 2004). Additional consequences were related to
pressure and stigma that failure to prescribe would conclude that the physician is
acting inhumanely, and possible litigation for under-treatment of pain was possible.
Most noticeably, there was a rise in additional deficits and disabilities due to the
over-prescription, a rise in federal charges against pharmaceutical companies and
physicians, and most importantly, a rise in opioid-related misuse and deaths. As a
response to the current epidemic, we are experiencing, laws and policies were
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created to limit the prescription of opiates and address the addiction that is likely to
occur. However, individuals found alternative methods to address those addictions,
using the black market and street heroin and increased use and preference for
fentanyl (Jones et al., 2018; Morales et al., 2019). Emphasis on alternative methods
and combined treatment methods have been implemented to address further the
epidemic we face. As it relates, empirical data and literature will be explored
relative to treatment funding as well as types and phases of treatment.
Treatment Funding. Because drug abuse and addiction are considered
major health problems, treatment is facilitated in many different areas. Along with
the specialized drug treatment facilities, addiction is also treated in physician
offices and mental health clinics by various providers (NIDA, 2020). The severity
of the substance abuse problem creates the need for treatment funded by local,
State, and Federal governments. Implementation of policies such as the Affordable
Care Act (ACA) expands coverage for addiction treatment in the insurance plans. It
expands criteria to other marketplaces that include behavioral health services
(Andrews et al., 2018). Private and employer-subsidized health plans are likely to
provide coverage for treatment. However, challenges are still evident in receiving
adequate care due to financial, social, technical, and cultural factors (Frimpong &
Guerrero, 2020). In these factors, it becomes evident that the programs with higher
percentages of minority clients depend heavily on public funds such as Medicaid
reimbursement and state block grants. These funds provide lower financial support
and coverage needed for staff and maintain electronic health records. However,
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programs serving higher percentages of white clients are likely to have more
private insurance or self-pay, donations, integrated medical and mental health
services, and electronic health records with quality improvement strategies
implemented (Frimpong, & Jiang, 2014). Therefore, considering location and
demographics, the best treatment outcomes are likely to be displayed in individuals
who can engage in private and self-pay. This difference in treatment and access to
resources directly affects the patient's comfortability and, therefore, adherence to
the treatment plan.
Phases of Treatment. The early forms of substance use treatment became
viewed as cruel and unusual punishments, with the medical community
acknowledging that addiction can be treated through more humane methods. The
idea was accepted that brain chemistry is altered through regular substance use,
leading to behavioral changes and unavoidable drug-abusing behaviors, and created
drug dependence that is likely best treated by pharmacological and therapeutic
methods (NIDA, 2007). Individuals experience different stages and phases of
addiction treatment compared to previous experiences. Intake involves meeting
with a professional to discuss treatment options with a personalized treatment plan
based on assessing the medical, emotional, behavioral, and social functioning. The
inclusion of co-occurring and dual diagnoses treatment allows for additional
treatment options to be explored that address the mental illnesses coupled with a
substance use disorder (NIDA, 2018). These treatment options can be identified in
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phases of treatment and additional options for individuals diagnosed and battling
with OUDs.
Detoxification Phase. Detoxification is the stage in which an individual is
experiencing withdrawal syndromes that may involve uncomfortable and possibly
dangerous symptoms. Supervision, monitoring, and pharmacological interventions
are utilized to assist in detoxification (NIDA, 2018). These interventions address
the markedly unpleasant and often dangerous symptoms individuals’ experience.
Historically, detoxification was misunderstood in terms of certain substances,
which often made the process more difficult, created complications, and potentially
lead to death. Due to continuous scientific research and studies, professionals better
understand utilizing substances to ease certain drugs' withdrawal symptoms,
including heroin and prescription opioids (NIDA, 2019). A medically supervised
detox utilizes certain medications that depend on the specific substance that is
being abused (NIDA, 2018). While the specific pharmacotherapeutic procedure is
likely to differ, the type of substance dependence and the potential severity
associated with the withdrawal symptom is often similar.
Rehabilitation and Support Phase. Like the timeframe and extent of
detoxification, the necessity and types of treatment programs available and
explored by the individual are similar. Inpatient treatment programs are utilized to
separate the individual from the environments conducive to continuous substance
use and prove harmful and problematic. The facilities offer continuous care and
monitoring for the individual in an environment meant to assist in rehabilitation.
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These environments serve as a positive alternative to teach new ways of life for the
individual and their road to recovery. They are also geared towards individuals with
severe and extensive addictions and often used to stabilize that individual.
Residential treatment also offers 24-hour care but is often in a non-hospital setting,
focusing on the individual's resocialization. The residential treatment programs can
be short-term or long-term stays, relative to the individual's needs and their
substance of choice as main factors (NIDA, 2020). The program uses the staff,
residents, and established social comradery to help individuals establish
accountability and routine to return to society (NIDA, 2018) eventually.
Outpatient and Rehabilitation Programs. However, individuals with
family and work obligations tend to have difficulty finding inpatient facilities that
can accommodate their schedules for extended periods. Even with facilities that
have programs specific to families, and work-study, the idea is that the individual
will eventually enter back into society and learn to maintain recovery with the
support of the systems they developed during inpatient or residential treatment
(NIDA, 2020). Outpatient programs are then a good option for those individuals
that need recovery assistance that would allow them to maintain those
responsibilities. Likewise, outpatient services are more equipped to manage milder
addictions and sustain sobriety. There are also intensive outpatient programs that
are direct services for individuals with substance use disorders or co-occurring
mental and substance use disorders that do not require medical detoxification or 24hour supervision (McCarty et al., 2014). Still, they are designed to establish
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psychosocial supports and facilitate relapse prevention and coping mechanisms;
they have been essential in the continuum of care for those individuals.
Transitional, aftercare, and recovery support programs are also utilized, such as
sober living homes and halfway houses, to assist in continued recovery care relative
to the individual needs' accountability before going back to their homes.
Additionally, in all treatment programs, Alcoholics Anonymous (A.A.) and
Narcotics Anonymous (N.A.) meetings are offered, required, and encouraged by
the facilities to ensure continued engagement in the recovery community.
Recovery Support Groups. Self-help therapy, such as Narcotics
Anonymous (N.A.) and Alcoholics Anonymous (A.A.) groups, emphasize that
individuality and one single treatment method will not produce effective recovery
(Rasmussen, 2000; Steps, 1981). In these groups and meetings, individuals discuss
the difficulties and experiences they have had with substance use disorders, the
effect on their family and their lives, and their recovery process. The literature on
the components of N.A. and A.A. that make it beneficial has had limited research.
However, it has been shown that individuals referred to 12-step groups had better
alcohol and drug use outcomes at six-months, and ultimately 12-step involvement
being a partial mediator between outcome and condition (Timko, DeBenedetti, &
Billow, 2006). Studies have also shown that the interconnectedness of spirituality,
self-efficacy, coping, and social support are intricate components that facilitate
change (Groh, Jason, & Keys, 2008). Individuals who engage in these groups tend
to have higher levels of social support from peers and benefit more than individuals
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with fewer friends and less stable social network composition. Essentially, the
stages of recovery of the individuals and felt level of the community assist in
abstaining from substance use.
Additional factors that have been considered to the effectiveness of
recovery support groups are the inclusion of other protective components. For
instance, sponsorship is an essential component of recovery, and studies have
shown that having a sponsor increased involvement and recovery outcomes (Ryan
& Tonigan, 2012). Likewise, an individual's view on natural supports such as
family and perceived environmental stressors can affect their likelihood of
completing treatment requirements and maintaining sobriety. For instance, courtordered participants have indicated that recovery support groups tend to be the
most beneficial aspects of drug court, which encouraged completion of the program
(Gallagher & Wahler, 2018). However, similar to the literature, factors such as their
environment, culture, and family support can also become indicators that hinder the
likelihood of recovery maintenance (Gallaher, 2013). Because of the limited nature
of how support groups work, more literature would need to be conducted to
illustrate further the effectiveness of support groups related to perceived
environmental stressors.
Therapeutic and Psychosocial Treatment Phase. An essential addition to
substance use disorders is the utilization of therapeutic techniques in conjunction
with substance abuse treatment. With the shifting view of substance use disorders,
scientists and medical professionals understand that the therapy aspect of treatment
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is specific to addressing long-term recovery by getting to the core of the reasons for
addiction (NIDA, 2018). This aspect addresses the issues they have experienced in
the past and will likely face in the future but with alternative and more positive
coping mechanisms in play to address those issues to deter them from relapse.
Individual therapy often addresses core difficulties, trigger identification, coping
mechanisms, time management, and reconstruction of thinking patterns.
Additionally, Group and Family therapy are often encouraged to help
resolve issues that have contributed to the individual's substance use and are likely
to hinder the recovery process (NIDA, 2018). It is also utilized to foster connection
and cohesion with the support system that the individual is likely to need during reentry into society. Likewise, case management and peer recovery are offered to
assist in the tangible aspects that would hinder an individual from re-acclimating to
society. Occupational, educational, and vocational exploration are often included in
this treatment aspect.
Medication-Assisted Treatment (MAT)
In addition to traditional substance use disorder treatments such as inpatient
or outpatient, MAT has been implemented. This treatment combines medications
such as methadone, buprenorphine, or naltrexone, with counseling and behavioral
therapies. These three FDA-approved medications are used to treat cravings and to
prevent relapse. The three medications are ligands that bind to and target the muopioid receptors that are necessary for the therapeutic activity (Connery, 2015).
However, they differ in their intrinsic activities at the mu-opioid receptor and the
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pharmacokinetic and pharmacodynamics properties. They also differ in the
mechanisms that confer relapse-prevention protection to the treated individual.
While methadone has been recognized as one of the older and more widely utilized
forms of MAT for OUD, there have also been many difficulties with regulation
regarding weaning and sex differences.
Methadone. Methadone has a proven success rate in the treatment of OUD.
However, individuals on this medication have a lower likelihood of successful
titration without implementing an alternative medication or substance (Dervan,
Yaghmai, Watson, & Wolf, 2017). Likewise, similar to opioid abuse and
dependence, individuals utilizing methadone often undergo detoxification and
withdrawal from the substance itself due to its inherent properties. For this
particular study, the use of methadone, while acknowledged as a potential
treatment, will not be explored in this study.
Buprenorphine and Suboxone. Buprenorphine is a partial agonist. The
medication activates the opioid receptors to a lesser extent than full agonists
(Lewis, 1985). While Buprenorphine can have similar effects as full agonists (i.e.,
fentanyl, heroin, morphine, and oxycodone), it loses effectiveness at higher doses
(Johnson, Fudala, & Payne, 2005). Buprenorphine can be used as a pain reliever,
but when taken correctly, it does not create the euphoric state that is associated with
substances such as morphine or heroin. It has also been demonstrated to have a
good safety profile, low physical dependences, and flexible dosing schedules
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(Johnson, Strian & Amass, 2003). Likewise, it will prevent withdrawal symptoms
and reduce cravings for opiate drugs when used correctly.
Medications such as Subutex and Suboxone contain buprenorphine.
Subutex was developed first, and opioid users have been found to inject the drug
intravenously to obtain the high they would experience from other drugs such as
heroin and prescription medications. Therefore, Suboxone was created to combat
that tendency. Suboxone contains both buprenorphine and naloxone. Naloxone is
an opioid antagonist, which blocks the effects of the opioids at the receptor site
(Johnson, Fudala, & Payne, 2005). Buprenorphine and naloxone have been
evaluated as an analgesic combination used to reduce potential abuse, including
inpatient-controlled paradigms (Robinson, Dukes, Robinson, Cooke, & Mahoney,
1993). If an individual attempts to inject Suboxone, they will go into precipitated
withdrawal, which tends to distress the individual. Severe addictions, or those
diagnosed with a moderate or severe diagnosis code, are seeing more use of
Suboxone than Subutex because of naloxone and the reduced likelihood of abuse.
Suboxone is administered as a sublingual tablet, placed under the tongue until it is
dissolved. Suboxone is available in two dosage strengths: 2 mg buprenorphine with
0.5 mg naloxone and 8 mg buprenorphine with 2 mg naloxone. Appropriate dosage
and titration of medication to the individual will be specific to the facility and
individual's needs. Suboxone provided sublingually was developed to reduce the
potential of abuse in supervised dosing and make it more difficult to remove
(Lintzeris et al., 2013). The sublingual version dissolves faster than the tablets and
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reduces the likelihood that individuals will misuse the substance later through
crushing or snorting, as is the case with the tablets. Suboxone is the focus of this
particular study.
Naltrexone and Vivitrol. Naltrexone is a long-acting antagonist at the
opioid receptors that block the subjective and objective responses of the medication
that is produced by intravenous opioid use (Gonzalez & Brogden, 1988).
Naltrexone has also been studied as favorable and effective treatment for alcohol
use disorder relative to reduced drinking and the number of drinks consumed on
such days, compared to placebos (Sawicka & Tracy, 2017). Likewise, studies have
shown that naltrexone treatment efficacy improves alcohol abstinence over time
across various outcome measures for individuals who completed treatment and
were highly compliant with taking the medication (Blanco-Gandia & RodriguezArias, 2018; Volpicelli et al., 1997). Additional studies have indicated that oral
naltrexone helps reduce heroin cravings. Highly motivated patients have shown
favorable treatment success rates during naltrexone therapy, remaining opioid-free
longer than less motivated patients (Volpicelli, Alterman, Hayashida, & O'Brien,
1992). However, studies have also shown that extended-release naltrexone versus
oral naltrexone tablets can improve adherence and decrease discontinuation, as it is
administered as an intramuscular injection approximately every 28 days and not
daily (Krupitsky et al., 2011; Morgan, Schackman, Leff, Linas, & Walley, 2018).
Family support, psychotherapy, and counseling, combined with naltrexone
therapy, showed a greater likelihood of remaining opioid-free. Research has
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indicated that naltrexone is beneficial in reducing opioid use. Retention such as
contingency management is vital in treating opioid dependence with naltrexone
(Johansson, Berglund, & Lindgren, 2006). Vivitrol is an FDA-approved extendedrelease injectable form of naltrexone. An individual must be at least seven to ten
(and sometimes fourteen days) post-detox from opioid use before utilizing Vivitrol.
It is a once-monthly extended-release injectable (380 mg) non-addictive and nonnarcotic and should be used as part of a management program that includes
psychosocial support (Syd & Keating, 2013; Vivitrol, n.d.). Studies have indicated
that individuals utilizing Vivitrol and remained in management programs have had
higher senses of control over their use and lower recidivism rates (Rieckmann,
Garvey, Srikanth, Andrich, & Gregg, 2015). Although Vivitrol is made available to
many facilities, the utilization appears to be more prominent in high-restriction
treatment facilities.
Suboxone and Vivitrol Comparison. The medication that individuals
choose is often related to their stage of sobriety and availability of medications. For
instance, patients who are not already opioid-free, Suboxone is preferable to
Vivitrol, when both are clinically appropriate and indicated (Knopf, 2018).
Suboxone addresses severe OUDs of individuals in which complete detoxification
would be dangerous and difficult. Likewise, although both medications are
comparably effective and safe options, agonists (Suboxone) treatment is often
encouraged when induction or initiation into antagonist (Vivitrol) treatment is not
successful (Lee et al., 2018). Individuals with more severe OUDs have reported
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that Vivitrol effectiveness decreases before the next injection, and individuals
experience cravings for opioids (Knopf, 2019). This occurrence increases the
likelihood of opioid overdose death, injury, or coma if an individual tries to
challenge the opioid blockade (Binswanger & Glanz, 2018). However, Suboxone
can be misused and abused. Individuals prescribed Suboxone may take more than
prescribed to receive an opiate high (Cicero, Ellis, Surratt, & Kurtz, 2014).
Individuals may abuse Suboxone recreationally, finding that places with high
heroin abuse rates also report Suboxone abuse. For example, Suboxone can be
snorted, and the film strips can be dissolved and then injected, with injections
causing a much more intense high than snorting the pills. (Bazazi, Yokell, Fu, Rich,
& Zaller, 2011; Ferrant et al., 2011).
In terms of reducing overdose deaths, Vivitrol appears to be more costeffective. The benefit is expressed in the individual's increased quality of life and
years of opioid abstinence (Murphy et al., 2017). It is also reflected in the decrease
in the need for high-cost healthcare services such as emergency department visits
and the cost of overdose deaths. The extended-release component allows for more
extended periods of not needing to return for dosages and craving reduction
(Morgan, Schackman, Leff, Linas, & Walley, 2018). However, it does not appear to
be more cost-effective using generally accepted value thresholds for quality of life,
willingness to pay, and the high price (Murphy et al., 2017; Murphy et al., 2019).
Individuals are often unable to pay for the extended-release injection and the
reduction of effectiveness over the days tends to vary. However, suppose state
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addiction treatment payers can assist and offset the payment required for the
injection. In that case, the medication could be a cost-effective option for reducing
opioid overdose deaths (Jackson, Mandell, Johnson, Chatterjee, & Vanness, 2015).
Relatedly, Suboxone prescriptions appear to be written more than Vivitrol.
Assumptions indicate more familiarity with Suboxone, less painful detoxification
processes, and euphoric association differences between the two (Andraka-Christou
& Capone, 2018; Nguyen, Andraka-Christou, Simon, & Bradford, 2019; Vranken
et al., 2017). Both medications are met with significant insurance barriers, such as
extensive pre-authorization processes. However, the monthly injection's high cost is
often met with more barriers than that of Suboxone. Therefore, while both
medications' success rates have appeared to be high, individuals with insurance and
means to engage in inpatient treatment are more likely to engage in Vivitrol
treatment; however, this is relative to education on Vivitrol and the severity of
OUD.
Access to treatment options is often dependent upon race, income,
geography, and insurance status rather than individual preferences of medical or
psychiatric indicators. A cross-sectional study indicated that counties that were of
highly segregated African American/Black and Hispanic/Latino communities
utilized more methadone facilities (Goedel et al., 2020). In contrast, those counties
with highly segregated Caucasian/White communities utilized more buprenorphine
facilities. Additional studies indicate that buprenorphine treatment has increased in
higher-income areas with lower percentages of African American/Black,
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Hispanic/Latino, and low-income residents. In comparison, methadone rates remain
stable over time and continue to collect in urban low-income areas (Amiri,
McDonell, Denney, Buchwald, & Amram, 2020). Black/African Americans in the
U.S. with OUDs were less likely to receive buprenorphine than Whites (Cioe et al.,
2020). The individuals who were able to self-pay or had private insurance
represented nearly 74 percent of those who received buprenorphine treatment from
2012-2015. Buprenorphine is also an office-based treatment program that often
only works for patients with access to primary care practitioners to prescribe and
administer, likely inaccessible to low-income or uninsured individuals. The use of
Vivitrol generated minimal information on the demographics of its users, as the
effect of race has not been explored thoroughly. However, the general observation
has been that Caucasian males are more likely to seek and obtain substance use
treatment than other populations. Therefore, those related treatment indicators such
as insurance, income, race/ethnicity, and geographic location also imply barriers for
patients and clinicians who do not meet the favored criteria.
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Chapter 3
Rationale for Proposed Study
The growing frequency of OUD and overdose deaths involving opioids has
reached epidemic levels since the 1990s (Rudd, Seth, David, & Scholl, 2016).
Between 2002 and 2018, the prevalence of heroin use and disorder has nearly
doubled (Han, Volkow, Compton, & McCance-Katz, 2020). The use of illicit
synthetic opioids such as fentanyl has also increased in the United States. It is
reported that approximately two-thirds of people who primarily use heroin have
also reported a comorbid utilization of prescription opioids (Rosenblum et al.,
2007). According to the literature, the" first opioid of choice" is frequently a
prescription opioid and not heroin (Cicero, Ellis, Surratt, & Kurtz, 2014). Taken
together, there are different routes for an individual to develop an OUD which
contributes to a continued public health concern. Relatedly, the need to further
understand the available treatment options dedicated to addressing the disorder
remains to be a necessity in research.
Addictive use of substances such as opium and heroin, along with drugrelated crime (especially in poor urban communities), increased concern of those
with social, religious, and political leadership (Center for Substance Abuse
Treatment, 2005). The increasing challenges in the face of the individuals using
opioids are related to access to the substance relative to treatment access. The
development of MAT uses medications, in conjunction with counseling and
behavioral therapies, to provide a different approach to treating the substance use
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disorder (McCance-Katz, 2018). The goals of using MAT are to focus on
increasing the individuals' survival rate, increase maintenance of treatment,
decrease delinquency amongst the substance users, assist in maintaining
employment, and improve pregnant women's birth outcomes using the substance.
The development of Vivitrol and Suboxone medications is related to continued
research of identified substances that can assist the patient in achieving and
maintaining recovery.
There is empirical support that MAT is a positive reduction of opioid use
disorder-related symptoms, reducing the risk of infectious disease transmission and
criminal behavior associated with substance use (NIDA, 2020). Individuals
utilizing buprenorphine/naloxone (Suboxone) of 16 mg or more per day were 1.82
times more likely to stay in treatment and decreased the number of opioid-positive
drug tests by 14.2 percent (Mattick, Breen, Kimber, & Davoli, 2014; NIDA, 2020).
Likewise, extended-release injectable naltrexone (Vivitrol) produced 90 percent
confirmed abstinent weeks compared to 35 percent in a placebo study group
produced in Russia (Krupitsky et al., 2011; NIDA, 2020). The substances'
effectiveness is similar to treatment but different in administration and obtaining
the medications. Thus, this research aims to explore the use of the identified MATs
and how they have been utilized to treat OUD.
In detail, this study evaluates the application of Suboxone and Vivitrol in a
treatment facility to assess how these medications address opioid addiction and
recidivism (or the likelihood of relapse). By evaluating the adherence of individuals
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to the proposed treatment methods of MAT through outpatient and inpatient
treatment options, the objective is to assess how identified demographic factors
affect the adherence to the treatment and admission to the available programs.
Additionally, the objective is to evaluate how these treatment options can be
assessed to provide additional support for MAT services and modifications for
future use related to demographic markers.
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Chapter 4
Objectives and Hypotheses
Objective 1: To determine if there is a notable difference in the enrollment into
MAT from individuals utilizing inpatient and outpatient services. Although
medically assisted "detoxification" treatment is considered to have restricted
efficiency as a stand-alone treatment route, it often functions as the link between
abstinence and maintenance treatment (National Collaborating Centre for Mental
Health, 2008). A hospital setting permits a higher level of medical supervision and
safety for individuals who require intensive monitoring (Day & Strang, 2011).
Inpatient treatment also allows for interruption of cyclic drug use even in the
absence of medically dangerous symptoms. With more comprehensive inpatient
settings, individuals can focus attention on the precipitating familial, vocational,
medical, and psychiatric issues.
However, outpatient treatment options require the individual to be subjected
to the daily situations they are likely to encounter on discharge, which is likely to
promote more effective coping skills but the equal risk of relapse. The reported rate
of successful completion of opioid detoxification varies between 4% and 100% in
studies, with higher rates in studies conducted in an inpatient setting (Day, 2005;
Day & Strang, 2011). Additionally, MATs are exercised after individuals have
completed detoxification and sustained abstinence for at least a week or more,
which may present as problematic for outpatient settings (Nunes et al., 2018).
Considering this information, it is expected that there will be more individuals
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enrolling in MAT that have utilized inpatient services than outpatient services
alone.
Hypothesis 1.
There will be higher rates of inpatient MAT treatment enrollment than
outpatient.

Objective 2: To determine if there is a notable difference in seeking and enrolling
into MAT options of Vivitrol and Suboxone. Vivitrol and Suboxone are proven to
both be plausible MAT options. Buprenorphine products have steadily become the
most commonly prescribed and accessible forms of evidence-based opioid
treatment (Jones, Campopiano, Baldwin, & McCance-Katz, 2015; Lee et al., 2018).
Extended-release injectable naltrexone was developed to provide sustained opioid
receptor blockage, improve long-term adherence, and improve overall effectiveness
(Morgan, Schackman, Leff, Linas, & Walley, 2018). There are, however,
differences in the administration of the treatment and the adherence to the treatment
regimen. Both medications are equally safe and effective.
However, studies have shown difficulty with the initiation of individuals
into the use of Vivitrol, continued adherence, and lower relapse-free survival than
Suboxone due to early induction failure (Connery, 2015; Lee et al., 2018).
Suboxone has been proven to be preferable for patients who are not already opioidfree because Vivitrol requires patients to be detoxed for at least a week (Knopf,
2018). Likewise, Vivitrol, compared to Suboxone, was not represented to be more
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cost-effective, even after accounting for savings from fewer follow-up visits
associated with Vivitrol (Murphy et al., 2017). Suboxone use to Vivitrol use is
more likely to take place because it appears more desirable to the patients, even
though Vivitrol tends to have a lower likelihood of abuse. Considering this
information, it is expected that there will be more Suboxone admissions than
Vivitrol admissions.
Hypothesis 2.
There will be higher rates of Suboxone MAT enrollment than Vivitrol MAT
enrollment as it relates to the cost differential.

Objective 3: To determine if there is a noted gender difference for engagement of
MAT. Substance abuse treatment has been shown to benefit both women and men
engaging in comprehensive services such as educational, housing, income support
services, and post-treatment services (Marsh, Cao, & D'Aunno, 2004). Men and
women differ concerning the patterns of substance use disorders, their
physiological responses to the substances, psychiatric comorbidities discovered,
and barriers to treatment (Chen, Strain, Crum, & Mojtabai, 2013). Men tend to
engage in treatment through recommendation or mandate by social institutions such
as employers or the criminal justice system whereas, women tend to enter treatment
through social work referrals (Grella & Joshi, 1999).
Women are also shown to have more severe and diverse difficulties at
treatment intake than their male counterparts. When addressing employment and

MEDICATION ASSISTED TREATMENT

34

medical problems, via interventions to reduce overdose risk after heroin abstinence,
treatment for opioid dependence is likely to reduce mortality risk for men (Evans et
al., 2015). By attending to the concurrent use of other substances such as
methamphetamine or cocaine and opioids, treatment for opioid dependence is likely
to reduce mortality risk among women. Opioid overdose deaths among women
have increased fivefold in the past decades. This problem is now recognized as a
national epidemic among both women and men (CDC, 2013a; CDC, 2013b).
However, women are still typically outnumbered by men in opioid treatment
settings by approximately 3 to 1 (Brady & Ashley, 2005; Evans et al.; Nosyk et al.,
2014). Considering this information, it is expected that there will be more males
engaging in MAT programs than females.
Hypothesis 3.
There will be more MAT treatment enrollment by males than females.

Objective 4: To determine if there are noted differences among enrollment into
MAT programs as it relates to race/ethnicity. There are noted concerns about the
structural and programmatic barriers associated with MAT provisions and
utilization (McElrath, 2018). Many of the concerns are related to the racial/ethnic
disparities represented. For instance, racial/ethnic minorities with OUD often suffer
worse health outcomes that are related to their involvement with the criminal
justice system, increased exposure to violence, and experiences with medical
complications (Alegria, Carson, Goncalves, & Keefe, 2011; Pro, Utter, Haberstroh,
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& Baldwin, 2020). White individuals are more likely to engage in treatment due to
access to care, awareness of care, and financial and community resources exercised
for substance use care. Likewise, studies show that racial/ethnic minorities
experienced lower treatment retention rates and completion and more prolonged
treatment episodes than their White counterparts (Mennis & Stahler, 2016; Mennis
et al., 2019; Stahler & Mennis, 2018). Considering this information and the cited
gender differences, it is expected that White (Caucasian) males will be more likely
to utilize MAT services than any other demographic group. It also important to
notate the stigma associated with seeking treatment that can be self-induced but
also related to policy makers and lack of education which creates barriers for
treatment and hinders allocation of resources (Luoma et al., 2013; Yang, Wong,
Grivel, & Hasin, 2017).
Hypothesis 4.
Caucasian males will utilize MAT services more than any other
demographic group.

Objective 5: To determine if there are income and employment-related differences
amongst individuals that engage in MAT services. The literature provides that
individuals meeting criteria for disability and low-income backgrounds count on
Medicaid assistance to offset the cost of healthcare (McElrath, 2018). However,
many states and programs within states do not permit Medicaid payments for
services provided by an opioid treatment program. Likewise, several insurance
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companies do not cover the cost of these programs. Nonwhite racial/ethnic groups,
which generally have lower income than whites and experience more significant
healthcare disparities, are the fastest-growing population of opioid users in the
United States (Colby and Ortman, 2015; Wu, Zhu, & Swartz, 2016). The ability to
afford the treatment, more established treatment facilities, and additional tangible
resources to maintain treatment all represent barriers for lower-income individuals.
Although some states expanded Medicaid coverage for substance use disorder
treatment, low socioeconomic groups likely do not have coverage (Ali et al., 2017;
Buck, 2011; Andrews et al., 2019; Pro, Utter Haberstroh, & Baldwinn, 2020).
Considering this information, it is expected that employed individuals will be more
likely to engage in the MAT programs than their unemployed counterparts. Those
under the poverty line will likely be offered Vivitrol more than those employed due
to the medication's lasting effects but are likely to utilize Suboxone more due to
cost.
Hypothesis 5.
Individuals who are employed will have greater enrollment admission to
Suboxone and Vivitrol MAT programs than unemployed individuals.

Objective 6: To determine the effect of education level on engagement in MAT.
Individuals with low education levels often experience limited job prospects and
poor economic options, leaving them susceptible to drug addiction. These persons
likely reside in rural areas, have fewer resources to address drug addiction, and are
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often vulnerable to financial incentives to participate in acts related to opioids (Ho,
2017; Scommegna, 2018). Studies have discovered that individuals with an OUD
are likely to have lower educational attainment and lower-income (Blanco &
Volkow, 2019). Thus, research questions the connection between educational
attainment and chance of engaging in MAT services, which includes adherence to
the program, cost-effectiveness of use, and additional psychosocial responsibilities.
Studies have also shown that years of life lost due to drug overdose increased for
all education groups of male and female, with drug overdose accounting for
significant educational gradients in life expectancy for non-Hispanic Whites (Ho,
2017). This information provides that as the drug overdose and use increases, the
educational attainment decreases. Likewise, studies show that opioid users achieve
lower education levels, resulting in both individual and economic costs (Ellis,
Kasper, & Cicero, 2020). Therefore, the relationship between MAT enrollments
becomes a question as it relates to educational attainment and employment.
Hypothesis 6.
Higher educational attainment will increase an individual’s prospect of
enrollment to Suboxone and Vivitrol MAT programs as it relates to
employment status.
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Chapter 5
Methods
Via an application and initial review by the Florida Institute of Technology
Institutional Review Board (Project #21-056), the IRB informed the researchers of
the project’s exempt status, with permission granted for use of archival data. The
data was provided by a data collection and storing system generated by Gateway
Community Services (GCS). Established in 1978 and located in Northeast Florida,
GCS is a facility with various treatment and recovery-based forms of services,
including detoxification, behavioral and psychosocial rehabilitation (such as
counseling, case management, and peer recovery) MAT. This program also
provides patient-centered care that produces a combination of individual and group
counseling and support groups. They also provide inpatient (residential) and
outpatient treatment options with self-pay, private, and public insurance options.
Additionally, they offer medications such as Suboxone and Vivitrol, with education
for the use of either. This facility was chosen due to the assortment of treatment
programs offered to the patient, extensive knowledge of use and diagnoses of
substance use disorders, and the longevity of the facility's commitment to substance
use.
Sample
A 2018-2019 data sample was used from GCS. The data from 973 adult
treatment participants at GCS was included for analyses. The participants ranged in
age from 18 to 85-years-old, each experiencing different recovery stages that range
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from 1-750 days. There was also a range of substance use diagnoses available. For
this research, the emphasis was placed on heroin and other opioid diagnoses with
various substance use diagnoses and opioid treatment. However, the individuals
included were specific to opioid-related diagnoses and engaged in MAT services.
Individually identifiable information was removed before analysis to protect
participant anonymity, and group summary results were included. However,
individuals were provided informed consent at the time of data collection.
Variables
Demographic information was collected for each of the individuals. This
demographic information included: age (no date of birth), sex, race, ethnicity,
marital status, parental status, education level, employment status, annual family
income, length of program enrollment in days, and reason for discharge from the
program. Other variables explored were: the primary, secondary, and tertiary
substance use diagnoses; individuals identifying as completing treatment (Yes or
No); those using MAT treatment (Suboxone (Yes or No); Vivitrol (Yes or No); and
the individuals identified as using heroin/opioids (Yes or No). To illustrate
inpatient services, individuals identified as engaging and completing designated
inpatient services. To illustrate outpatient services, variables such as which
outpatient services were included for analysis were included. The questionnaire
was not included for this study due to lack of access of the variables that were not
utilized in the study.
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Data Modification. Archival data was originally collected by GCS staff
evaluators who administered client assessments upon client application and entry to
the treatment facility. Additionally, GCS staff entered and coded the data into the
central GCS database. The individuals provided information on their drug of choice
when completing the assessment. Likewise, urinalysis was collected at the entry of
the facility. Individuals involved with MAT and Vivitrol services are also drug
screened before receiving medication to ensure that individuals are detoxed and do
not have other substances in their system that would interfere with the substance's
treatment effectiveness at the time of administration. At the time of administration,
authorization of release forms and multiple consent forms were collected from the
individual for treatment and collection of the information utilized. The data used
for the current study represented a 2018-2019 data sample for the facility.
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Chapter 6
Results
Participants
A total of 1023 participants were utilized in the sample. Of this total, 50
cases were removed due to missing values and overlapping information that did not
maintain the parameters necessary for discrimination regarding compliance data.
As distinguishing between individuals identified as using one or the other MAT
services was important, participants who did not use one or the other, or identified
as using both MATs offered at the facility during their engagement in the program,
were all removed. Therefore, 973 cases remained and were reviewed for this study.
Among the remaining 973 participants, 49% identified as Male (n = 477)
and 51% identified as Female (n = 496). Relative to race, 86.9% (n = 846)
identified as White, 6.1% (n = 59) identified as Black, 5.7% (n = 55) identified as
Multi-Racial, and individuals identifying as “Other” in the table configuration were
composed of 1.0% (n = 10) identifying as American Indian/Alaskan, 0.1% (n = 1)
Hawaiian/Pacific Islander, and 0.2% (n = 2) Asian for a total of 1.34% (n=13). Of
the participants, 4.5% (n = 44) identified as being of Hispanic decent and 95.5% (n
= 929) identified as Non-Hispanic. See Table 1 for further participant
demographic information.
Pertaining to employment, 30.5% (n = 297) of individuals identified as
having some source of employment, and 69.5% (n = 676) identified as
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unemployed. See Table 2 for further participant employment and education
information.
As it relates to education, 36% (n = 36) identified as having a 5th to 8thgrade education, 21.3% (n = 207) identified as having a 9th to 12th-grade education
with no diploma, 38.1% (n = 371) identified as having a High School Diploma,
21.3% (n = 207) identified as having some college but no degree, 2.3% (n = 22)
identified as having Vocational or Trade degrees, and 13.4% (n = 130) identified as
having an Associates, Bachelors, or Master’s degree.
Statistical Analyses
Inpatient and Outpatient Enrollment. When analyzing the data for
inpatient and outpatient services, it was discovered that 51.2% (n = 498) of the
patients involved in MAT services utilized a service identified as “Medical
Services.” This episode is to be identified as both inpatient and outpatient services.
This episode of care was controlled for, and analysis was further conducted on
episodes of care that were identified as inpatient versus outpatient services.
To explore whether there were differences between individuals utilizing
inpatient and outpatient MAT services, a Chi-Square was conducted illustrating
Suboxone use (yes or no), Vivitrol use (yes or no), and Program Value (inpatient or
outpatient). The results indicated that there was a significant difference between
Inpatient and Outpatient MAT service users (X2(36.53, N=475) = 1, p<.01).
However, there were more outpatient (51.2% (n = 243) MAT service users than
inpatient (48.8% (n = 232) MAT service users. Likewise, of the participants,
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32.3% (n = 153) utilized Suboxone and were of outpatient services and, 42.5% (n
= 202) utilized Suboxone in inpatient services. Relatedly, 18.9% (n = 90) utilized
Vivitrol in an outpatient service and 6.3% (n = 30) used Vivitrol in an inpatient
episode. See Figure 3 and Figure 4 for further information on the Chi-square
distribution output of inpatient versus outpatient on Suboxone MAT services.
This information did not support the hypothesis that there would be more
inpatient service enrollment than outpatient. When controlling for “Medical
Services,” more outpatient service episodes utilized MAT services than individuals
in inpatient episodes. Conversely, more individuals in inpatient episodes appeared
to utilize Suboxone services than those in outpatient episodes.
MAT Service Differences Selection. To explore whether there were
differences in Suboxone and Vivitrol use, a Chi-square analysis illustrating
Suboxone use (yes or no) and Vivitrol use (yes or no) was conducted. The results
indicated that there was a significant difference between Suboxone and Vivitrol
users (X2(973, N=973) = 1, p<.01). Of the participants, 77% (n = 749) identified as
having utilized Suboxone and 23% (n = 224) identified as using Vivitrol. See
Figure 5 for further information on the Chi-square distribution output of Suboxone
versus Vivitrol MAT services.
This information supported the hypothesis that there would be more
Suboxone MAT enrollment than Vivitrol MAT enrollment related to cost
differential. The process of enrolling into Suboxone appears to illustrate a
preference for the substance when both Suboxone and Vivitrol are available.
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Factors such as cost-effectiveness, the process of enrollment, and adherence are
likely to play a part in selection of Suboxone to Vivitrol.
MAT Enrollment and Gender Differences. To explore whether there
were differences in Suboxone and Vivitrol use related to gender differences, a Chisquare analysis illustrating Suboxone use (yes or no), Vivitrol use (yes or no), and
Gender (male or female) was conducted. The results indicated that there was a
significant difference (X2(14.72, N=973) = 1, p<.01) for Suboxone and Vivitrol use.
Analyses indicated that 82.1% (n = 407) of Females and 71.7% (n = 342) of Males
chose Suboxone MAT services. Likewise, 17.9% (n = 89) and 28.3% (n = 135) of
Males chose Vivitrol MAT services. See Figure 6 and Figure 7 for further
information on the Chi-square distribution output of Patients Gender on Suboxone
and Vivitrol MAT services.
This information did not support the hypothesis that there was more female
MAT treatment enrollment than male enrollment. It appears that more women were
selecting Suboxone treatment for opioid use than men in this particular facility.
Likewise, it is noted that although women outnumbered men, there were slightly
more men selecting Vivitrol treatment enrollment compared to women.
Caucasian/White Male MAT Service Differences. To explore
demographic differences with the assumption that Caucasian/White Males being
more expected to enroll in MAT services than Non-White Male demographic
groups, a Chi-square analysis was utilized with Suboxone (yes or no), Vivitrol (yes
or no), and White Male (yes or no) identifications. There was a significant
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difference (X2(6.988), N=973) = 1, p <.05). Of the participants, 42.3% (n = 412)
identified as White Males, and 57.7% (n = 561) identifying as Non-White Male
demographic standing. Of the White Males, 40.1% (n = 300) utilized Suboxone
and 50.0% (n = 112) used Vivitrol. See Figure 8 and Figure 9 for further
information on the Chi-square distribution output of White Male’s versus NonWhite (Other Demographic Representatives) on Suboxone and Vivitrol MAT
services.
This information did not support the hypothesis that Caucasian/White Males
would be more likely to utilize MAT services than any other demographic group.
Although they accounted for approximately 42% of the population, 45% of the
population of individuals utilizing MAT services were Caucasian/White females.
Likewise, neither group accounted for more than 50% of the population.
Employment Differences and MAT services. To explore employment
differences and utilization of MAT services, a Chi-Square analysis illustrating
Suboxone (yes or no), Vivitrol (yes or no), and Employment (employed vs. notemployed) was conducted. There was not a significant difference (X2(.866, N=973)
= 1, p >.05). Unemployed individuals accounted for 69.5% (n = 676) and
Employed individuals accounted for 30.5% (n = 297). Unemployed individuals
utilizing Suboxone were 70.2% (n = 526) of the population, and employed
individuals using Suboxone were 29.8% (n = 223). Of the individuals using
Vivitrol, 67% (n = 150) were unemployed, and 33% (n = 74) were employed. See
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Figure 10 and Figure 11 for further information on the Chi-square distribution
output of Employed versus Unemployed on Suboxone and Vivitrol MAT services.
This information did not support the hypothesis that employed individuals
will be more likely to be admitted to MAT programs. Unemployed individuals
outnumber employed individuals, which illustrates that employment is not
predictive of enrollment to the programs.
Educational Attainment, Employment, and MAT Service Differences.
To explore differences between MAT services and Higher Educational attainment,
a Chi-square analysis was conducted. To illustrate this distinction, analyses of
Suboxone (yes or no), Vivitrol (yes or no), and Education (Higher Education or
High School Diploma and Those Having Less Than a High School Diploma) were
conducted. The results indicated that there were statistical differences as it relates
to education and MAT services (X2(20.02), N=973) = 1, p <.01). Suboxone users
without higher education accounted for 51.5% (n = 501) and with higher education
accounted for 25.5% (n = 248). Vivitrol users without higher education accounted
for 11.6% (n = 113), and with higher education accounted for 11.4% (n = 111) of
the total population. See Figure 12 and Figure 13 for further information on the
Chi-square distribution output of Higher Education versus High School Diploma
and Less on Suboxone and Vivitrol MAT services.
An Analysis of Variance (ANOVA) test was run to explore how higher
educational attainment affects individuals’ likelihood of enrollment to MAT
services programs as it relates to employment status. This ANOVA test was used to

MEDICATION ASSISTED TREATMENT

47

illustrate variance amongst variables such as Suboxone (yes or no), Vivitrol (yes or
no), Employment (employed or unemployed), and Education (interval clustering).
There was no significant effect of educational attainment on employment [F
(5,967) =.721, p=.608].
There was, however, a significant effect of Suboxone and Vivitrol use on
educational attainment at the interval clustering level. [F (5,967) = 11.41, p< .01].
A Tukey Post Hoc test indicated that Suboxone (M =.77, SD=.421), Vivitrol (M
=.23, SD=.421), and Education attainment (M =3.85, SD=1.58) were statistically
significant at the College Degree comparison relative to other educational
identification such as 5th to 8th grade (p<.01), 9th to 12th grade, no diploma (p<.01),
High School Graduate/Diploma/Degree (p<.01) and Some College, No Degree
(p<.01). However, there was no statically significant difference between College
Degree and Vocational/Trade (p=.65). Therefore, obtaining a college degree and
engaging in Suboxone or Vivitrol treatment did not happen by chance and having
post-secondary education made a difference.
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Chapter 7
Discussion
Impact of Study
Over the past decades, Opioid Use Disorder has continuously been a global
epidemic and public health problem. The call for proper treatment and access to
care has been sharply increasing as the mortality rates of opioid-related deaths also
increase (Ma et al., 2019). The utilization of MAT services has been explored to
combat those deaths. Despite national data projections of the prevalence of OUDs
surpassing approximately 5 million and growing in the United States, only a
fraction of the population received MAT treatment services in the past ten years
(Zheng et al., 2017; Andrilla, Patterson, Moore, Coulthard, & Larson, 2020). The
engagement of this study explored the population that uses MAT services to
understand better the trajectory of use, enrollment, and program-related
functionality. It also provided indications for populations that are still needing to
receive access to care.
The inpatient and outpatient hypothesis indicated that individuals in
outpatient treatment settings are more likely to engage in MAT services than in
inpatient settings. Some have suggested that the benefits to inpatient services such
as medically supervised withdrawal from substances, removal of outside
influences, psychosocial support, and continued monitoring would reduce relapse
potential (Nunes et al., 2018). However, it is noted that facilities use short inpatient
treatment stays, and often facilities rarely distinguish between patients who receive
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medications in inpatient or outpatient services because they fall under an umbrella
of care. Nonetheless, facilities could increase their prescribing rate by identifying
needed services for inpatient and outpatient individuals, including linkage to
follow-up services and medication management (Hagedorn et al., 2018). In order to
gain more clarity in the distinction of inpatient and outpatient services, more
defined identification and coding should be used to assist with assessing unmet
program needs.
Next, the results indicated that there were more Suboxone MAT service
users than Vivitrol service users. The distinction between the two substances was
made and able to be readily identified. Fifty participants illustrated the use of both,
meaning that they engaged in both of the substances at one point in their treatment
trajectory. The participants were removed to ensure that the data would be correctly
observed. However, the results indicated a significant difference between the two,
with approximately 77% being Suboxone MAT users, and therefore, the 50
participants were not likely to affect the results in general. This information was
predicted relative to the literature on selecting services and benefits for engaging in
both services. Explored reasons are related to the idea that Vivitrol discontinuation
rates appear to be higher in the first injection related to cost, insurance, and
retention rates, compared to Suboxone use, which also deters desirability of MAT
by patients (Morgan, Schackman, Leff, Linas, & Walley, 2018). Likewise, other
rationale includes the administration structure of Suboxone, the candidacy for
office-based treatment pathways, and reduction of the high need for strict
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adherence to medication management compared to Vivitrol (Tran, Griffin, Stone,
Vest, & Todd, 2017). These similar benefits are likely reasons for exploration in
the GCS, but further research would be beneficial to explore as both treatments
have proved effective.
Relative to demographic hypotheses, gender differences were explored.
Women represented more of the MAT population service use than men. The
literature supports the idea that men were more likely to engage in all MAT
services and more likely to engage in MAT service trials and research which
represented a possible bias in the literature (Ling, Mangaoil, Cleverley, Sproule, &
Puts, 2019). A vital notation to be made is that men were selecting Vivitrol
treatment options more than women, even though they were outnumbered as a
whole. Vivitrol treatment has been proven to be well-tolerated by pregnant women
who choose to detoxify off opioid drugs during gestation completely, which tends
to be opposed by most women (Towers, Katz, Weitz, & Visconti, 2020). Although
pregnancy was not asked of participants, future studies would benefit from
inclusion of this criteria to illuminate the impact of pregnancy as it relates to the
preference for Vivitrol treatment. There was also a declared need for more women
involvement in MAT services in general, especially considering the high rate of
pregnant women with OUDs (Krans, Kim, James, Kelley, & Jarlenski, 2019).
Relatedly, GCS has a program dedicated to pregnant women and substance use but
is also engaged in child welfare services and drug court, which could have
accounted for the higher engagement rate of women in the MAT services. Further
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analysis would have to be conducted to illustrate and assess a possible link of
related episodes of care to women’s exploration of MAT services. Further research
should also be explored on the use of MAT services by women related to social
functioning, psychological symptoms, treatment barriers, and gender differences
(Van Reekum et al., 2020).
Additionally, racial differences were explored. Caucasian men were
projected to use MAT services more than any other demographic group. Although
Caucasian men accounted for a high percentage of the population, they did not
account for a statistically significant portion of the individuals that sought MAT
services at GCS. It is important to note that Caucasian men and women accounted
for approximately 87 percent of the total population of individuals in MAT
services. This information does correlate with literature in that White individuals
are more likely to utilize MAT services even though these services have been
proven to be beneficial to other demographic populations (Stahler, Mennis, &
Baron, 2021). Additional studies should be conducted to explore the racial
disparities to reduce the racial gap of individuals engaging in these OUD treatment
services.
Further, employment differences were explored in this research. Individuals
employed did not account for a significant portion of the population of those in
MAT services. This information represents that employment is not indicative of
enrollment in the program. It would be advantageous to explore the additional
rationale for engagement in the programs related to cost such as insurance and
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private pay instead of employment rates. This detailed information was not
collected in the study, which would be beneficial to analyze in correlation.
Likewise, literature exploring employment acknowledges that treatment duration
and engagement is not impacted by employment (Brydsten, Hammarstrom, & San
Sebastian, 2018; McBrien et al., 2019; Van Reekum et al., 2020). However, older
age increases the odds for employment, associations between unemployment and
poorer health outcomes have been well-studied, and women tend to report being
unemployed more than men in MAT services. Therefore, with consideration to
these factors for future studies, the outcome would likely be more salient with the
literature. Likewise, future literature should be explored to understand further how
MAT services such as selecting various MAT substances correlate with continued
employment and job maintenance.
Related to employment demographic information, educational attainment
and MAT services were explored. There was no significant effect of employment
on educational attainment, according to the results of this study. MAT services on
education attainment relative to levels of education were significantly affected
where individuals illustrating higher education achievement and college degree
achievement showed a significant difference in choosing to engage in MAT
services. The literature supports the idea that individuals with higher education,
precisely a graduate degree, likely had more positive attitudes towards MAT
services such as Vivitrol use (Andraka-Christou, Gabriel, Madeira, & Silverman,
2019). The literature also supported the idea that employed individuals or students
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were nearly 2.5 times more likely to graduate in drug court-related programs than
individuals who were not (Gallagher et al., 2018). Likewise, offering MAT services
to those employed or educated individuals was projected to improve graduation
rates for drug courts. Although these results were indicated, there are still many
individuals who do not seek higher education and engage in MAT services. Future
research should explore the inter-correlation of employment and education on MAT
services. Research should also be geared towards understanding if higher education
is a factor for individuals in the programs and ways to provide increased education
for those interested but hesitant due to lack of awareness.
Limitations and Areas for Future Study
The first significant limitation was the inability to distinguish between
inpatient and outpatient services that have affected the first hypothesis test.
Although “medical services” was able to be controlled with the idea that there was
an equal distribution of the patients in the episode, it would have been preferred to
make the distinction that could account for both inpatient and outpatient services
more seamlessly. This information would be beneficial to establishing the
relationship between the individuals that used Suboxone and Vivitrol and
placement in the programs. Future research should focus on how programs
effectively make this distinction to account for the services that are working well
for individuals in MAT services.
Additionally, there was minimal information for how many times an
individual’s service count (the number of services an individual received) was
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presented and an inability to have a direct indicator for follow-up for a year or more
after completing the episode. This information means that there is no way to
evaluate whether or not the individual checked into another treatment facility, is
since deceased, or relapsed and did not return to the facility. This difficulty is the
same for individuals that leave the Vivitrol or Suboxone program. Having the
information for these episodes of care and the timeline of the individuals’ treatment
would allow for additional information that gives a better understanding of the
completion of care and likely barriers to completion of care.
Another limitation is related to the fact that the study was specific to one
treatment facility and cannot account for the statistics; however, the attempt of
using such a large sample size was to be able to generalize to more demographics.
Also, connecting with other treatment facilities to evaluate their use of data
collection and treatment forms would allow for more generalizability.
Conclusion
In conclusion, to acknowledge the public health difficulty of opioid use
disorder, the likelihood of enrollment into MAT services was explored. The
research concluded that more outpatient serviced individuals have used MAT
services than their inpatient counterparts. In comparison to one another, Suboxone
treatment is still being utilized more than Vivitrol treatment. Demographic
information explored that more women than men have been using MAT services.
Furthermore, individuals that have obtained degrees greater than a high school
diploma represent a significant population of note for MAT services as well.
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Likewise, employment does not have an acknowledged effect on engaging in MAT
services despite education being a qualifying factor. However, without follow-up
data for the individuals’ that completed services, such as a survey tracking their
current standing or use of MAT, it is not possible to identify what path the
individuals’ took after completing the episode of care or current enrollment in
treatment. Likewise, using additional treatment facilities and a direct clarification
of episodes of care would be beneficial to further assessment of the route of the
individuals in the programs.
In order to prevent relapse, assess for improvements, and sustain recidivism,
all of the limitations must be addressed. It is important to educate the staff as well
as the individuals receiving treatment, to continue to understand their rights and the
benefits of maintaining sobriety. By increasing awareness of the options for
individuals with opioid related substance use disorders, there could be a decrease in
the number of lives claimed by this opioid epidemic. Future research should be
geared towards addressing the demographic related issues, limitations, and
comparison of other treatment facilities to identify and attend to barriers to
treatment.
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Table 1

Means and Standard Deviation for Adult Demographic Information
Sex/Race/Ethnicity %
Sex
Female

51.0

Male

49.0

M
1.49

SD
.500

1.95

.208

7.57

1.20

Ethnicity
Spanish/Latino

4.52

None of the Above

95.48
Race

Other

1.34

Black

6.06

Multi-Racial

5.65

White

86.95

Total

100
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Table 2
Means and Standard Deviation for Adult Demographic Information
Education/Employment

Percentages M
Education
3.85

5th to 8th grade

3.70

9th to 12th grade, no diploma

21.27

SD
1.58

High School graduate/diploma/ degree 38.13
Some college, no degree

21.27

College Degree AA, BA, MS degrees

13.36

Vocational/Trade School

2.26
Employment
30.52

Employed
69.48
Unemployed
Total

100

1.69

.461
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Figure 1.
Frequency Statistic of Identification of Suboxone MAT service Variable
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Figure 2.
Frequency Statistic of Identification of Vivitrol MAT service Variable
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Figure 3.
Chi-square Frequency Distribution of Inpatient vs Outpatient on Suboxone MAT
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Figure 4.
Chi-square Frequency Distribution of Inpatient vs Outpatient on Vivitrol MAT
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Figure 5.
Chi-square Frequency Distribution of Suboxone vs Vivitrol MAT Service
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Figure 6.
Chi-square Frequency Distribution of Patient Gender on Suboxone MAT
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Figure 7.
Chi-square Frequency Distribution of Patient Gender on Vivitrol MAT
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Figure 8.
Chi-square Frequency Distribution of White Male vs Others on Suboxone MAT
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Figure 9.
Chi-square Frequency Distribution of White Male vs Others on Vivitrol MAT
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Figure 10.
Chi-square Frequency Distribution of Employed Vs Unemployed on Suboxone
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Figure 11.
Chi-square Frequency Distribution of Employed Vs Unemployed on Vivitrol
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Figure 12.
Chi-square Frequency Distribution of Education on Suboxone MAT
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Figure 13.
Chi-square Frequency Distribution of Education on Vivitrol MAT
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